secwatch.observer — SEC 8-K summary
======================================

Issuer:     Karyopharm Therapeutics Inc. (KPTI)
CIK:        0001503802
Form:       8-K
Filed at:   2026-08-13T11:37:30+00:00
Accession:  0001193125-26-347897
Event type: earnings
Sentiment:  negative
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Karyopharm Q2 net loss $67M; cash runway only to Sept 2026, sNDA on track
-------------------------------------------------------------------------

- Q2 2026 total revenue $33.4M (vs $37.9M YoY); U.S. XPOVIO net product revenue $30.8M (vs $29.7M).
- Net loss $67.0M ($2.32/share) vs $37.3M loss ($4.32/share) in Q2 2025; operating loss $22.5M.
- Cash $65.4M at June 30; expects funding only into Sept 2026; $15.8M term loan payment due Sept 10, 2026 may trigger default.
- Planned August sNDA for selinexor+ruxolitinib in myelofibrosis under Accelerated Approval; FDA feedback supports SVR35 as surrogate.
- Phase 3 XPORT-EC-042 endometrial trial missed primary endpoint (PFS); median PFS 12.75 vs 7.43 months, HR 0.76, p=0.0791.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1503802/000119312526347897/0001193125-26-347897-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1503802/000119312526347897/kpti-20260813.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-347897

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer